US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AgomAb Therapeutics

8.95

+0.15001.70%

Volume:161.60K

Turnover:1.43M

Market Cap:440.77M

PE:-1.98

High:9.15

Open:8.88

Low:8.60

Close:8.80

52wk High:17.82

52wk Low:7.97

Shares:49.25M

Float Shares:13.84M

Volume Ratio:0.75

T/O Rate:1.17%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.5143

EPS(LYR):-168.1598

ROE:-39.22%

ROA:-20.58%

PB:4.26

PE(LYR):-0.05

Loading ...

Overview Company News Filings

Agomab, FDA Agree on Phase 2b Trial for Crohn's Disease Treatment

Agomab announces NOV-ERA study design

Agomab wins FDA alignment for NOV-ERA Phase 2b design in fibrostenosing Crohn’s disease

Agomab Announces Design of Nov-Era Phase 2B Study With Ontunisertib in Fibrostenosing Crohn’s Disease

THOMSON REUTERS

AgomAb Therapeutics Initiated at Buy by HC Wainwright & Co.

Agomab initiated with a Buy at H.C. Wainwright

Agomab Therapeutics Nv : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $35

THOMSON REUTERS

U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon

Agomab Therapeutics holds annual general meeting, backs board reappointments

Press Release: Agomab Announces Results of Annual General Meeting

Wall Street Analysts Are Bullish on Top NA Picks

Press Release: Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

Agomab FY25 net loss widens 35% to EUR 62.5 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/AGMB/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AGMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":8.95,"timestamp":1791484412115,"preClose":8.8,"halted":0,"volume":161601,"delay":0,"changeRate":0.01704545454545438,"floatShares":13836000,"shares":49248000,"eps":-4.51426,"marketStatus":"Trading","change":0.15,"latestTime":"10-08 14:35:53 EDT","open":8.88,"high":9.1506,"low":8.6,"amount":1429437.7670759999,"amplitude":0.062568,"askPrice":9.08,"askSize":300,"bidPrice":8.91,"bidSize":118,"shortable":3,"etf":0,"ttmEps":-4.51426,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791489600000},"marketStatusCode":2,"adr":0,"adrRate":1,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":8.8,"preHourTrading":{"tag":"盘前","latestPrice":9.38,"preClose":8.8,"latestTime":"09:25 EDT","volume":162,"amount":1493.8399080000002,"timestamp":1791465951702,"change":0.58,"changeRate":0.065909,"amplitude":0.043182},"postHourTrading":{"tag":"盘后","latestPrice":8.8,"preClose":8.8,"latestTime":"19:30 EDT","volume":96,"amount":875.09,"timestamp":1791415801277,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.751872},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","floatShares":13836000,"roa":"-20.58%","roe":"-39.22%","lyrEps":-168.159829,"volumeRatio":0.751872,"shares":49248000,"dividePrice":0,"high":9.1506,"amplitude":0.062568,"preClose":8.8,"low":8.6,"week52Low":7.97,"pbRate":"4.26","week52High":17.82,"institutionHeld":0,"latestPrice":8.95,"committee":-0.435407,"eps":-4.51426,"divideRate":0,"volume":161601,"delay":0,"ttmEps":-4.51426,"open":8.88,"prevYearClose":16,"prevWeekClose":8.56,"prevMonthClose":11.1,"prevQuarterClose":11.1,"fiveDayClose":8.65,"twentyDayClose":13.94,"sixtyDayClose":12.63},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGMB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGMB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AGMB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1787716800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AGMB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AGMB","date":"2026-10-07","current":-1.982606,"percent":0.981928,"low":-14.725744,"twenty":-11.037468,"median":-8.730463,"eighty":-7.534496,"high":-5.642551,"avg":-9.331832,"sd":2.239588,"marketCap":435352099},"quantilePoints":[{"date":"2026-02-06","current":-14.293959,"twenty":-14.293959,"median":-14.293959,"eighty":-14.293959,"marketCap":779788464},{"date":"2026-02-13","current":-13.901135,"twenty":-14.202947,"median":-13.85921,"eighty":-13.805127,"marketCap":763217959},{"date":"2026-02-20","current":-13.975141,"twenty":-14.020702,"median":-13.811207,"eighty":-13.436782,"marketCap":760781120},{"date":"2026-02-27","current":-14.297833,"twenty":-14.274685,"median":-13.837477,"eighty":-13.631029,"marketCap":780275831},{"date":"2026-03-06","current":-12.944797,"twenty":-14.315694,"median":-13.869306,"eighty":-13.479283,"marketCap":692549629},{"date":"2026-03-13","current":-12.71107,"twenty":-14.294734,"median":-13.805127,"eighty":-12.961754,"marketCap":677928595},{"date":"2026-03-20","current":-11.600011,"twenty":-14.274685,"median":-13.584093,"eighty":-12.695924,"marketCap":618957093},{"date":"2026-03-27","current":-10.84065,"twenty":-14.216331,"median":-13.160447,"eighty":-12.395453,"marketCap":578505566},{"date":"2026-04-02","current":-10.748527,"twenty":-14.066263,"median":-13.052487,"eighty":-11.414439,"marketCap":574119256},{"date":"2026-04-10","current":-9.193391,"twenty":-13.930737,"median":-12.827934,"eighty":-10.709469,"marketCap":497602513},{"date":"2026-04-17","current":-10.018749,"twenty":-13.86294,"median":-12.650405,"eighty":-9.901184,"marketCap":545851924},{"date":"2026-04-24","current":-9.622204,"twenty":-13.825362,"median":-12.457995,"eighty":-9.650988,"marketCap":521483535},{"date":"2026-05-01","current":-7.206485,"twenty":-13.809991,"median":-11.744798,"eighty":-9.486381,"marketCap":528794052},{"date":"2026-05-08","current":-7.639457,"twenty":-13.779732,"median":-11.111376,"eighty":-9.258769,"marketCap":562411874},{"date":"2026-05-15","current":-7.446972,"twenty":-13.702513,"median":-10.748527,"eighty":-8.300034,"marketCap":543697644},{"date":"2026-05-22","current":-7.434647,"twenty":-13.568448,"median":-10.364346,"eighty":-8.115636,"marketCap":538772846},{"date":"2026-05-29","current":-7.796965,"twenty":-13.4527,"median":-9.998785,"eighty":-7.794875,"marketCap":568321631},{"date":"2026-06-05","current":-8.053102,"twenty":-13.287949,"median":-9.784729,"eighty":-7.758816,"marketCap":585558422},{"date":"2026-06-12","current":-6.750851,"twenty":-13.127527,"median":-9.578953,"eighty":-7.536224,"marketCap":486569993},{"date":"2026-06-18","current":-6.929006,"twenty":-13.073014,"median":-9.501773,"eighty":-7.448225,"marketCap":497404547},{"date":"2026-06-26","current":-9.2886,"twenty":-13.035188,"median":-9.467948,"eighty":-7.458553,"marketCap":661400304},{"date":"2026-07-02","current":-8.166663,"twenty":-12.965993,"median":-9.467948,"eighty":-7.479819,"marketCap":584573463},{"date":"2026-07-10","current":-8.975013,"twenty":-12.944797,"median":-9.309036,"eighty":-7.532768,"marketCap":641701114},{"date":"2026-07-17","current":-8.479177,"twenty":-12.71107,"median":-9.193391,"eighty":-7.541408,"marketCap":606735052},{"date":"2026-07-24","current":-8.981683,"twenty":-12.707304,"median":-9.020605,"eighty":-7.554336,"marketCap":638746235},{"date":"2026-07-31","current":-8.723327,"twenty":-12.661785,"median":-8.978348,"eighty":-7.610114,"marketCap":628157921},{"date":"2026-08-07","current":-9.22434,"twenty":-12.557349,"median":-9.00807,"eighty":-7.636377,"marketCap":664847662},{"date":"2026-08-14","current":-8.931525,"twenty":-12.519309,"median":-9.035172,"eighty":-7.716456,"marketCap":686763011},{"date":"2026-08-21","current":-8.496488,"twenty":-12.423423,"median":-8.981683,"eighty":-7.781927,"marketCap":661400304},{"date":"2026-08-28","current":-8.778373,"twenty":-12.380686,"median":-8.974146,"eighty":-7.796268,"marketCap":681591974},{"date":"2026-09-04","current":-9.428222,"twenty":-12.300242,"median":-8.931525,"eighty":-7.867232,"marketCap":730347469},{"date":"2026-09-11","current":-8.858281,"twenty":-11.959423,"median":-8.973278,"eighty":-7.956453,"marketCap":686516771},{"date":"2026-09-18","current":-7.774516,"twenty":-11.657926,"median":-8.880371,"eighty":-7.795572,"marketCap":594915538},{"date":"2026-09-25","current":-6.876368,"twenty":-11.321652,"median":-8.807045,"eighty":-7.758992,"marketCap":521043575},{"date":"2026-10-02","current":-5.676951,"twenty":-11.106435,"median":-8.772569,"eighty":-7.554749,"marketCap":425994983},{"date":"2026-10-07","current":-5.836265,"twenty":-11.037468,"median":-8.730463,"eighty":-7.534496,"marketCap":435352099}],"updateTime":1791484553079},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AGMB\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645915854","title":"Agomab, FDA Agree on Phase 2b Trial for Crohn's Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2645915854","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645915854?lang=en_us&edition=fundamental","pubTime":"2026-06-24 05:14","pubTimestamp":1782249240,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics reached alignment with the Food and Drug Administration on the design of a Phase 2b study for patients with Crohn's disease who develop intestinal narrowings that can block food and often lead to surgery.The study will test Agomab's experimental pill, ontunisertib, against placebo in up to 320 adults, the Belgium-based company said Tuesday. Doctors will check at 24 weeks whether a scope can pass through the narrowed section of the intestine, which is a practical way to see if the blockage is easing. The trial will also follow patients to 52 weeks to track longer-term outcomes.Agomab said the protocol has been filed with the FDA and cleared a central ethics review in the U.S., and the study has Health Canada approval. The company has also submitted clinical trial applications in Europe and parts of Asia. The first patient is expected to be dosed in the second half of this year.Crohn's is a chronic progressive disease of the gastrointestinal tract. About 46% of all pa","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4588","LABU","BK4007","AGMB","BK4231","BK4585","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645485922","title":"Agomab announces NOV-ERA study design","url":"https://stock-news.laohu8.com/highlight/detail?id=2645485922","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645485922?lang=en_us&edition=fundamental","pubTime":"2026-06-24 04:18","pubTimestamp":1782245926,"startTime":"0","endTime":"0","summary":"Agomab (AGMB) announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal-restricted ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agomab-announces-nov-era-study-design-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agomab-announces-nov-era-study-design-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4179","BK4007","AGMB","LU1878469433.USD","NOV","LU0061475181.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645859954","title":"Agomab wins FDA alignment for NOV-ERA Phase 2b design in fibrostenosing Crohn’s disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2645859954","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645859954?lang=en_us&edition=fundamental","pubTime":"2026-06-24 04:06","pubTimestamp":1782245172,"startTime":"0","endTime":"0","summary":"Agomab secured FDA alignment on the Phase 2b NOV-ERA study design for ontunisertib in fibrostenosing Crohn’s disease.The protocol cleared central IRB review in the U.S. and received Health Canada authorization.First patient dosing is targeted for the second half of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL3YCkJP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","NDAQ","LU2210150020.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4588","SG9999014005.SGD","IE00BN0W2W23.USD","AGMB","BK4007","SG9999014021.USD","BK4585","LU2095319765.USD","SG9999014039.USD","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645859691","title":"Agomab Announces Design of Nov-Era Phase 2B Study With Ontunisertib in Fibrostenosing Crohn’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2645859691","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645859691?lang=en_us&edition=fundamental","pubTime":"2026-06-24 04:05","pubTimestamp":1782245100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA9TGKXQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029722","title":"AgomAb Therapeutics Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029722","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029722?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:11","pubTimestamp":1782126660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AGMB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 22, 2026 07:11 ET (11:11 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645026819","title":"Agomab initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2645026819","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645026819?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:05","pubTimestamp":1782122738,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio initiated coverage of Agomab (AGMB) with a Buy rating and $35 price target The firm says both of Agomab’s ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agomab-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agomab-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645025530","title":"Agomab Therapeutics Nv : H.c. Wainwright Initiates Coverage With Buy Rating  and Target Price $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2645025530","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645025530?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:01","pubTimestamp":1782122485,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nAZN4T3J2A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645042865","title":"U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon","url":"https://stock-news.laohu8.com/highlight/detail?id=2645042865","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645042865?lang=en_us&edition=fundamental","pubTime":"2026-06-22 15:47","pubTimestamp":1782114448,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, VisteonJune 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL4N42U0H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LINT","DAR","INTW","LRCX","BILL","CHRD","INTC","ENPH","INCY","AMAT","ALT","DFTX","KR","MRNX","ARMK","GLW","AALG","KLAC","NBIX","MUU","AGMB","LRCU","CNXU","LGN","FMC","VC","HCA","BWIN","DCH","MTDR","ABVX","FTH","MU","AMRZ","KLAG","MRK","KMX","MULL","LQDA","AAL","DAL","BYD","MRNA","APGE","ALGM","MRNY","FPS","BWXT","FANG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638550503","title":"Agomab Therapeutics holds annual general meeting, backs board reappointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2638550503","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638550503?lang=en_us&edition=fundamental","pubTime":"2026-05-27 17:00","pubTimestamp":1779872448,"startTime":"0","endTime":"0","summary":"Agomab held its annual general meeting on May 26, 2026.Shareholders adopted the statutory financial statements for the year ended Dec. 31, 2025.Shareholders granted discharge to current and former directors, plus the statutory auditor, for duties performed in 2025.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL8BnFDV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","NDAQ","LU2210150020.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4588","SG9999014005.SGD","IE00BN0W2W23.USD","AGMB","BK4007","SG9999014021.USD","BK4585","LU2095319765.USD","SG9999014039.USD","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638950336","title":"Press Release: Agomab Announces Results of Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2638950336","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638950336?lang=en_us&edition=fundamental","pubTime":"2026-05-27 17:00","pubTimestamp":1779872400,"startTime":"0","endTime":"0","summary":"Antwerp, Belgium, May 27, 2026 -- Agomab Therapeutics NV  , a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual General Meeting  held on Tuesday, May 26, 2026.-- Approval of the statutory financial statements for the financial year. -- Discharge to the current and former members of the Board of Directors and. the statutory auditor in respect of the performance of their respective. duties during the financial year ending on December 31, 2025.-- Reappointment of Mr. Ohad Hammer as a member of the Board of Directors. -- Reappointment of Mr. Tim Knotnerus as a member of the Board of Directors. Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab's product candidates are designed to target established potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","AGMB","BK4007","BK4229","AGM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636076558","title":"Wall Street Analysts Are Bullish on Top NA Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2636076558","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636076558?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:01","pubTimestamp":1779109297,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on AgomAb Therapeutics NV ADR (AGMB) and Standard Chartered (SC...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-na-picks-blurbs-news-8?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-na-picks-blurbs-news-8?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGMB","BLSG","BK4141","BLSX","BK4007","SCBFY","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629690438","title":"Press Release: Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2629690438","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629690438?lang=en_us&edition=fundamental","pubTime":"2026-04-24 06:14","pubTimestamp":1776982440,"startTime":"0","endTime":"0","summary":"-- Cash and Cash Investments at December 31, 2025 of EUR116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering  Expected to Extend Cash Runway into First Half of 2029 --. Pierre Kemula, Chief Financial Officer of Agomab, added, \"Thanks to the $208 million in gross proceeds raised from our IPO in February 2026, we are well-capitalized and we expect our cash reserves to last into the first half of 2029. With major milestones approaching later this year, we remain laser-focused on delivering on our corporate and clinical strategy.\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4007","IPO","BK4229","AGM","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629866477","title":"Agomab FY25 net loss widens 35% to EUR 62.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2629866477","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629866477?lang=en_us&edition=fundamental","pubTime":"2026-04-24 05:18","pubTimestamp":1776979127,"startTime":"0","endTime":"0","summary":"Agomab posted a net loss of EUR 62.5 million for fiscal 2025, widening 35%.Operating loss widened 23% to EUR 59.3 million.Research and development expenses climbed 24% to EUR 48.9 million, due to progress in clinical testing for ontunisertib and AGMB-447.Other operating income jumped 68% to EUR 2.4 million.Cash, cash equivalents and cash investments totaled EUR 116.5 million at Dec. 31, 2025; existing liquidity plus IPO proceeds expected to fund operations into the first half of 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Com","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDLbZTC6Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":53,"code":"91000000","status":"200"}]}}